Complete Guide to VRC07-523-LS Pharmacokinetics
Overview
VRC07-523-LS is a Broadly Neutralizing Antibody (bNAb) used in the HIV Prevention therapeutic area. It is indicated for HIV prevention in infants and adults. Population PK simulator for VRC07-523LS broadly neutralizing HIV antibody in infants and adults. Two-compartment model with zero-order SC absorption from Huynh et al. JAC 2026. Simulates concentration-time profiles and PT80 neutralization ratios.
Mechanism of Action
VRC07-523-LS exerts its pharmacological effect by targeting HIV-1 gp41/gp120. As a Broadly Neutralizing Antibody (bNAb), it modulates this target to achieve therapeutic efficacy in HIV prevention in infants and adults. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This 2-CMT PopPK model for VRC07-523-LS characterizes the time-course of drug concentrations following SC, IV administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
VRC07-523-LS is administered via the SC, IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the HIV Prevention therapeutic area, for the treatment of HIV prevention in infants and adults, understanding the pharmacokinetics of VRC07-523-LS is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect VRC07-523-LS pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive VRC07-523-LS PK Simulator
Explore VRC07-523-LS pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of VRC07-523-LS?
The elimination half-life of VRC07-523-LS depends on patient-specific factors. Use our interactive VRC07-523-LS PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is VRC07-523-LS administered?
VRC07-523-LS is administered via the SC, IV route. It is indicated for HIV prevention in infants and adults. As a Broadly Neutralizing Antibody (bNAb), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of VRC07-523-LS?
Key pharmacokinetic parameters for VRC07-523-LS include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a 2-CMT PopPK model to characterize the pharmacokinetics of VRC07-523-LS.
Can I simulate VRC07-523-LS dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive VRC07-523-LS PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.